MET and neoplasm: While, at the cut off value of >5% of tumour cells with positive immunostaining, 48% and 22% the cases were CD44 and c-MET positive respectively, only CD44 immunostaining of 3+ intensity was associated with a poorer overall survival in both univariate and multivariate analysis, and the c-MET/EGFR co-expression (HR = 3.05, p = 0.019) was associated with a poorer disease-free survival (Table 4).